Indications
— locally advanced or metastatic non-small cell lung cancer as first-line therapy in combination with cisplatin, as well as in monotherapy in elderly patients with performance status of 2;
— unresectable, mestorozhdenii or metastatic breast cancer in combination therapy with paclitaxel after neoadjuvant and/or adjuvant therapy with the inclusion of anthracyclines in the absence of contraindications to their destination;
— locally advanced or metastatic urothelial carcinoma (bladder cancer, renal pelvis, ureter, urethra);
— locally advanced or metastatic epithelial ovarian cancer as monotherapy or in combination with carboplatin in patients with disease progression after the first-line therapy on the basis of Latinoamerica drugs;
— locally advanced or metastatic pancreatic cancer;
— locally advanced or metastatic cervical cancer.
Reviews
There are no reviews yet